We hypothesized that plasma OPN may be a marker of treatment responsiveness and that genetic variations (polymorphisms) in the secreted phosphoprotein 1 (SPP1) gene, which encodes OPN, are associated with differences in GC responsiveness of patients with MG. This evidence concerns the gene SPP1 and myasthenia gravis.